Dental Pulp Stem Cells for Predictable Chronic Cerebral Palsy Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for cerebral palsy, particularly at the chronic stage, are ineffective and unpredictable due to the variability in stem cell differentiation and secretory factors, making it difficult to predict which stem cells will effectively improve symptoms.
Innovation Solution
The use of dental pulp stem cells, specifically human deciduous dental pulp stem cells characterized by high CD73, CD90, and CD105 positivity and low CD117 expression, administered in multiple doses to promote neurogenesis and improve motor and memory functions in subjects with cerebral palsy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesenchymal stem cells derived from umbilical cord blood are administered to cerebral palsy patients, then symptoms of cerebral palsy are improved, but the availability is limited because umbilical cord blood is rarely preserved at birth
Solution Approach 1:
The patent uses dental pulp stem cells as a substitute (copy) for umbilical cord blood mesenchymal stem cells. Both cell types exhibit similar therapeutic effects for cerebral palsy, but dental pulp stem cells are more readily available and can be obtained from deciduous teeth that would otherwise be discarded. This copying approach maintains the therapeutic reliability while significantly improving availability.
2Adaptability or versatility
If diverse stem cells are used for cerebral palsy treatment, then the potential therapeutic effects vary, but the ability to predict which stem cells will be effective is difficult due to differences in differentiation ability and secretory factors
Solution Approach 1:
The patent establishes specific parameter thresholds for dental pulp stem cells to ensure consistent therapeutic effects. The cells must express CD73, CD90, and CD105 at 30% or more of the cell population, and secrete BDNF at 10 pg/mL or more. By defining these precise parameters, the patent transforms the unpredictable variability of diverse stem cells into a standardized, predictable treatment protocol with reliable therapeutic outcomes.
3Adaptability or versatility
If stem cell transplantation is performed at the chronic stage of cerebral palsy, then treatment options are expanded beyond early intervention, but the effectiveness is reduced due to limited neuroplasticity and established neurological damage
Solution Approach 1:
The patent administers dental pulp stem cells in multiple sequential doses rather than a single transplantation. This preliminary action approach allows cumulative accumulation of therapeutic effects, where each dose builds upon the previous one. The repeated administration compensates for the reduced neuroplasticity at chronic stages by progressively promoting neurogenesis and functional recovery over time, thereby maintaining therapeutic reliability even when treatment is delayed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Dental pulp stem cells demonstrate a therapeutic effect on cerebral palsy, enhancing neurogenesis and improving motor and memory functions in subjects, particularly those with chronic cerebral palsy caused by hypoxia or ischemia.
Implementation Method 1
dental pulp stem cells have a prophylactic or therapeutic effect on cerebral palsy and a promoting effect on neurogenesis in the brain
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to an agent for preventing or treating cerebral palsy, comprising dental pulp stem cells, wherein the prevention or treatment agent is administered to a subject with symptoms of cerebral palsy.